Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus xevinapant versus placebo in older patients with locally advanced head and neck squamous cell carcinoma
NL-OMON59531Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant plus radiotherapy with Placebo plus radiotherapy (2 arms). Primary endpoint: Locoregional event-free survival. Started Dec 2023; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON59531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59531.